{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia%2C+Schizoaffective+Disorder%2C+or+Schizophreniform+Disorder",
    "query": {
      "condition": "Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T18:54:18.890Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02600741",
      "title": "Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Caregiver psycho-education and skills training",
          "type": "OTHER"
        },
        {
          "name": "Caregiver support available at the study site",
          "type": "OTHER"
        },
        {
          "name": "Paliperidone palmitate",
          "type": "DRUG"
        },
        {
          "name": "Chlorpromazine",
          "type": "DRUG"
        },
        {
          "name": "Droperidol",
          "type": "DRUG"
        },
        {
          "name": "Fluphenazine",
          "type": "DRUG"
        },
        {
          "name": "Haloperidol",
          "type": "DRUG"
        },
        {
          "name": "Loxapine",
          "type": "DRUG"
        },
        {
          "name": "Perphenazine",
          "type": "DRUG"
        },
        {
          "name": "Pimozide",
          "type": "DRUG"
        },
        {
          "name": "Prochlorperazine",
          "type": "DRUG"
        },
        {
          "name": "Thiothixene",
          "type": "DRUG"
        },
        {
          "name": "Thioridazine",
          "type": "DRUG"
        },
        {
          "name": "Trifluoperazine",
          "type": "DRUG"
        },
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Asenapine",
          "type": "DRUG"
        },
        {
          "name": "Clozapine",
          "type": "DRUG"
        },
        {
          "name": "Iloperidone",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Ziprasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 296,
      "start_date": "2015-07-24",
      "completion_date": "2018-07-05",
      "has_results": false,
      "last_update_posted_date": "2019-01-23",
      "last_synced_at": "2026-07-23T18:54:18.890Z",
      "location_count": 34,
      "location_summary": "Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more",
      "locations": [
        {
          "city": "Bullhead City",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Lauderdale Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02600741"
    },
    {
      "nct_id": "NCT01074632",
      "title": "Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder"
      ],
      "interventions": [
        {
          "name": "Lurasidone HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 26,
      "start_date": "2009-05",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2011-09-08",
      "last_synced_at": "2026-07-23T18:54:18.890Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Wichita, Kansas",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01074632"
    },
    {
      "nct_id": "NCT01731119",
      "title": "Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Schizophreniform Disorder",
        "Psychosis NOS",
        "Autistic Disorder",
        "Asperger Syndrome",
        "Child Development Disorders, Pervasive",
        "Bipolar I Disorder",
        "Bipolar II Disorder",
        "Mood Disorder NOS",
        "Severe Major Depression With Psychotic Features",
        "Single Episode Major Depression Without Psychotic Symptoms",
        "Severe Mood Disorder With Psychotic Features"
      ],
      "interventions": [
        {
          "name": "Latuda©",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "6 Years to 19 Years"
      },
      "enrollment_count": 9,
      "start_date": "2012-12",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-07-23T18:54:18.890Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01731119"
    },
    {
      "nct_id": "NCT01082250",
      "title": "The Bioequivalence Of Two Different Lurasidone Formulations In Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Lurasidone HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2008-07",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2011-09-08",
      "last_synced_at": "2026-07-23T18:54:18.890Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01082250"
    },
    {
      "nct_id": "NCT06041646",
      "title": "Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Schizophrenia",
        "Agitation,Psychomotor",
        "Schizo Affective Disorder",
        "Schizophreniform Disorders"
      ],
      "interventions": [
        {
          "name": "Sublingual film containing Igalmi",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioXcel Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 29,
      "start_date": "2023-10-02",
      "completion_date": "2024-04-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-02",
      "last_synced_at": "2026-07-23T18:54:18.890Z",
      "location_count": 2,
      "location_summary": "Little Rock, Arkansas • Rogers, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06041646"
    },
    {
      "nct_id": "NCT06002958",
      "title": "Horyzons: Implementation and Integration in Clinical Practice",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizophreniform Disorders",
        "Schizoaffective Disorder",
        "Unspecified or Other Psychotic Disorders"
      ],
      "interventions": [
        {
          "name": "Horyzons USA",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "16 Years to 35 Years"
      },
      "enrollment_count": 52,
      "start_date": "2024-01-08",
      "completion_date": "2024-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-09-18",
      "last_synced_at": "2026-07-23T18:54:18.890Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06002958"
    }
  ]
}